Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

An Open Library of Human Kinase Domain Constructs for Automated Bacterial Expression.

Albanese SK, Parton DL, Işık M, Rodríguez-Laureano L, Hanson SM, Behr JM, Gradia S, Jeans C, Levinson NM, Seeliger MA, Chodera JD.

Biochemistry. 2018 Aug 7;57(31):4675-4689. doi: 10.1021/acs.biochem.7b01081. Epub 2018 Jul 26.

PMID:
30004690
2.

High yield bacterial expression of active c-Abl and c-Src tyrosine kinases.

Seeliger MA, Young M, Henderson MN, Pellicena P, King DS, Falick AM, Kuriyan J.

Protein Sci. 2005 Dec;14(12):3135-9. Epub 2005 Oct 31.

3.
4.

Bacterial expression and purification of active hematopoietic cell kinase.

Kristelly R, Qiu TW, Gunn NJ, Scanlon DB, Mulhern TD.

Protein Expr Purif. 2011 Jul;78(1):14-21. doi: 10.1016/j.pep.2011.03.001. Epub 2011 Mar 6.

PMID:
21385611
5.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5. Epub 2002 Jul 29.

6.

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase.

Wang W, Marimuthu A, Tsai J, Kumar A, Krupka HI, Zhang C, Powell B, Suzuki Y, Nguyen H, Tabrizizad M, Luu C, West BL.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3563-8. Epub 2006 Feb 28.

7.

High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.

Szafran AT, Stephan C, Bolt M, Mancini MG, Marcelli M, Mancini MA.

Prostate. 2017 Jan;77(1):82-93. doi: 10.1002/pros.23251. Epub 2016 Oct 4.

8.

Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity.

Hill ZB, Perera BG, Maly DJ.

Mol Biosyst. 2011 Feb;7(2):447-56. doi: 10.1039/c0mb00108b. Epub 2010 Nov 9.

11.
12.

Recent advances in designing substrate-competitive protein kinase inhibitors.

Han KC, Kim SY, Yang EG.

Curr Pharm Des. 2012;18(20):2875-82. Review.

PMID:
22571656
13.
14.

A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).

Vainshtein I, Silveria S, Kaul P, Rouhani R, Eglen RM, Wang J.

J Biomol Screen. 2002 Dec;7(6):507-14.

PMID:
14599348
15.

Fast plasmid based protein expression analysis in insect cells using an automated SplitGFP screen.

Bleckmann M, Schmelz S, Schinkowski C, Scrima A, van den Heuvel J.

Biotechnol Bioeng. 2016 Sep;113(9):1975-83. doi: 10.1002/bit.25956. Epub 2016 Mar 10.

16.

Bacterial expression and characterization of catalytic loop mutants of SRC protein tyrosine kinase.

Kemble DJ, Wang YH, Sun G.

Biochemistry. 2006 Dec 12;45(49):14749-54.

PMID:
17144667
17.

Fluorescence properties of green fluorescent protein FRET pairs concatenated with the small G protein, Rac, and its interacting domain of the kinase, p21-activated kinase.

Collinson AD, Bligh SW, Graham DL, Mott HR, Chalk PA, Korniotis N, Lowe PN.

Assay Drug Dev Technol. 2004 Dec;2(6):659-73.

PMID:
15674024
18.

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.

Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, Hallek M.

Blood. 2003 Jan 15;101(2):664-72. Epub 2002 Sep 5.

19.

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.

Maekawa T, Ashihara E, Kimura S.

Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. Review.

PMID:
17929114
20.

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC.

Cancer Res. 2006 Jan 1;66(1):473-81.

Supplemental Content

Support Center